Cancer Control

Follow us for the latest research developments in the cancer control field (IF 2.6). Published in association with @MoffittResearch.

[Cancer Control @CancerControl_]

Reducing #FinancialToxicity in cancer care is not just about the intervention, it’s about implementation. Across 8 sites, operational data helped identify barriers and guide adaptations for more sustainable financial navigation. #Oncology #HealthEquity #CancerCare

[Cancer Control @CancerControl_]

#CancerScreening has impact only when systems can deliver diagnosis, referral, and treatment—not just detection. This Perspective discusses why cancer screening in resource-limited settings must be adapted to local capacity to achieve real #CancerControl impact. #GlobalHealth

[Cancer Control @CancerControl_]

#Delirium in hospitalized cancer pts is a major risk signal. In 126 pts w/ incident delirium, ~16% died in-hospital—linked to longer delirium, sepsis, low albumin/BMI/platelets, ↑LDH, and pre-delirium benzos. An actionable cue for earlier intervention. #Oncology #CancerCare

[Cancer Control @CancerControl_]

Childhood cancer survivors often miss survivorship care. Barriers: low awareness/need, anxiety/trauma, cost/insurance gaps, access (time/travel/housing), under-resourced services, tough pediatric→adult transition. #ChildhoodCancer #Survivorship #HealthEquity

[Cancer Control @CancerControl_]

Single-centre (@PeterMacCC) real-world data on #BiliaryTractCancer: 1st line gem/cis+ICI yields outcomes comparable to pivotal trials. ECOG & albumin predict survival. HER2 amp = worse OS; dMMR & BRCA = trend toward improved OS. Study highlights importance of molecular profiling.

[Cancer Control @CancerControl_]

Optimistic bias related adherence of metastatic #BreastCancer patients to oral anticancer treatments: negative association between adherence rate and self-perception of treatment adherence. Personality matters: conscientiousness = risk awareness; extraversion = overconfidence.

[Cancer Control @CancerControl_]

Higher state/local social + public health spending = fewer poverty-linked cancers. Top-spending states saw ~8% lower incidence and ~9% lower mortality. Investing upstream can cut cancer burden and narrow inequities. #Oncology #PublicHealth #SDOH #CancerPrevention #HealthEquity

[Cancer Control @CancerControl_]

A cross-sectional survey of 198 #BreastCancer specialists across Europe reports a strong endorsement of shared decision-making, but patchy uptake. Female physicians favour participatory styles. Digital #DecisionAids still underused compared to paper ones. #Communication #Oncology

[Cancer Control @CancerControl_]

Comprehensive review published in Cancer Control synthesizing #ClinicalTrials data on #OncolyticViruses (OVs) spanning 2013-2024. Provides an in-depth examination of OVs, highlighting their advancement from investigational modalities to clinical implementation. #ImmunoOncology

[Cancer Control @CancerControl_]

BRCA1/2-mutant early #BreastCancer: review urges region-tailored testing in Latin America, MRI-first screening, and shared surgical decision making. Neo-adjuvant platinum can raise pCR, while adjuvant olaparib improves OS. #BRCA #TNBC #PARPi #Latam

[Cancer Control @CancerControl_]

#EarlyOnsetCRC (<50) is rising & distinct: more left-sided/advanced disease, higher MSI-H/CIMP, and unique genomic/microbiome profiles. Action: lower screening age + risk-based, noninvasive, multi-omics/microbiome-guided care.
#ColorectalCancer #CRC #Screening #PrecisionOncology

[Cancer Control @CancerControl_]

Oncology visits with Black patients & non-Black physicians: higher physician #ImplicitBias → more nonverbal synchrony; higher patient trust → more patient-led synchrony. Takeaway: pair bias-mitigation with workflow/communication training to strengthen equitable care. #Oncology

[Cancer Control @CancerControl_]

Density and maturity of Tertiary Lymphoid Structures (TLS) may predict clinical outcome in invasive #LungCancer. In a 750 pt cohort, high intratumoral TLS density independently predicted better OS, while higher TLS maturation predicted worse outcomes. #ImmunoOncology

[Cancer Control @CancerControl_]

Analysis of #GBD2021 (204 countries) data reveals that #PancreaticCancer deaths tied to high #BMI have surged since 1990. Women still higher burden, but men rising faster, esp. ages 20–49 & low-SDI regions. #Obesity prevention + equity-focused policy needed. #GlobalHealth

[Cancer Control @CancerControl_]

Homelessness ↑ #HBV/#HCV risk. Community outreach in housing + drop-in sites linked ~2,000 Texans to care (≈2/3 needed services). Targeting engagement sites based on specific goals can help practitioners maximize outreach to high-need populations. #HealthEquity #PublicHealth

[Cancer Control @CancerControl_]

Pilot, co-designed brief decision aid for #ColorectalCancer #Screening, targeted to ages 75–85 with limited #HealthLiteracy.
20→8 pages;
understandability 44→75%, actionability 29→100%, clarity 71→~88.
Supports #SharedDecisionMaking; RCT next. #CancerScreening #CRC

[Cancer Control @CancerControl_]

A 4-week pilot in breast/colorectal cancer survivors testing continuous glucose monitoring (#CGM) + Fitbit + tailored texts was acceptable & shifted exercise readiness into action/maintenance. CGM biofeedback may help drive #PhysicalActivity; larger trials needed.
#DigitalHealth

[Cancer Control @CancerControl_]

In a survey of 1,357 Oregonians, Asian/Pacific Islander & unemployed/disabled adults reported more negative cancer beliefs & less confidence finding trustworthy info. Study highlight need for targeted, multilingual outreach via trusted channels to boost #CancerScreening & equity.

[Cancer Control @CancerControl_]

A pre-surgery prediction model using ultrasound, routine pathology, and simple blood tests, accurately flags axillary lymph-node spread in early #BreastCancer pts. In 287 pts it showed high accuracy and real clinical utility, supporting fewer unnecessary invasive procedures.

[Cancer Control @CancerControl_]

A routine blood score (SII) predicts patients with advanced non-small cell #LungCancer who benefit from PD-1/PD-L1 therapy. Low SII = higher response & longer PFS/OS, outperforming NLR/PLR. Data support using SII to guide selection & monitoring.
#NSCLC #Immunotherapy #Biomarkers